Valneva SE (VALN)
About Valneva SE
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $519.6M
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $519.6M
- Shares outstanding
- 108.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 6, 2021
Valneva SE (VALN) Stock Price
- Trading 61% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Valneva SE.
Write a review
News about Valneva SE
News & sentiment via Polygon.io
Valneva SE: frequently asked questions
Is Valneva SE an American company?
Valneva SE is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Valneva SE publicly traded?
Yes — Valneva SE is a publicly traded company. Its stock trades under the ticker symbol VALN on the NASDAQ.
What does Valneva SE do?
Valneva SE is an American Pharmaceuticals company in the Health & Beauty sector.
When was Valneva SE founded?
Valneva SE was founded in 2013.
